These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Waldenstrom Macroglobulinemia: Familial Predisposition and the Role of Genomics in Prognosis and Treatment Selection. Kapoor P; Paludo J; Ansell SM Curr Treat Options Oncol; 2016 Mar; 17(3):16. PubMed ID: 26942591 [TBL] [Abstract][Full Text] [Related]
6. An unusual case of cutaneous Waldenström macroglobulinemia with the MYD88 L265P mutation. Minzenmayer AN; Miranda RN; Powell PR; Parekh PK J Cutan Pathol; 2020 Sep; 47(9):850-853. PubMed ID: 32335928 [TBL] [Abstract][Full Text] [Related]
7. Management of Waldenström macroglobulinemia in 2020. Castillo JJ; Treon SP Hematology Am Soc Hematol Educ Program; 2020 Dec; 2020(1):372-379. PubMed ID: 33275726 [TBL] [Abstract][Full Text] [Related]
8. How to Sequence Therapies in Waldenström Macroglobulinemia. Sarosiek S; Treon SP; Castillo JJ Curr Treat Options Oncol; 2021 Aug; 22(10):92. PubMed ID: 34426943 [TBL] [Abstract][Full Text] [Related]
9. Molecular and genetic biomarkers implemented from next-generation sequencing provide treatment insights in clinical practice for Waldenström macroglobulinemia. Wang Y; Gali VL; Xu-Monette ZY; Sano D; Thomas SK; Weber DM; Zhu F; Fang X; Deng M; Zhang M; Hagemeister FB; Li Y; Orlowski RZ; Lee HC; Young KH Neoplasia; 2021 Apr; 23(4):361-374. PubMed ID: 33735664 [TBL] [Abstract][Full Text] [Related]
10. CXCR4 mutations affect presentation and outcomes in patients with Waldenström macroglobulinemia: A systematic review. Castillo JJ; Moreno DF; Arbelaez MI; Hunter ZR; Treon SP Expert Rev Hematol; 2019 Oct; 12(10):873-881. PubMed ID: 31343930 [No Abstract] [Full Text] [Related]
11. Novel Treatment Strategies in the Management of Waldenström Macroglobulinemia. Zanwar S; Abeykoon JP; Kapoor P Curr Hematol Malig Rep; 2020 Feb; 15(1):31-43. PubMed ID: 32006301 [TBL] [Abstract][Full Text] [Related]
12. Diagnosis and Management of Waldenström Macroglobulinemia: Mayo Stratification of Macroglobulinemia and Risk-Adapted Therapy (mSMART) Guidelines 2016. Kapoor P; Ansell SM; Fonseca R; Chanan-Khan A; Kyle RA; Kumar SK; Mikhael JR; Witzig TE; Mauermann M; Dispenzieri A; Ailawadhi S; Stewart AK; Lacy MQ; Thompson CA; Buadi FK; Dingli D; Morice WG; Go RS; Jevremovic D; Sher T; King RL; Braggio E; Novak A; Roy V; Ketterling RP; Greipp PT; Grogan M; Micallef IN; Bergsagel PL; Colgan JP; Leung N; Gonsalves WI; Lin Y; Inwards DJ; Hayman SR; Nowakowski GS; Johnston PB; Russell SJ; Markovic SN; Zeldenrust SR; Hwa YL; Lust JA; Porrata LF; Habermann TM; Rajkumar SV; Gertz MA; Reeder CB JAMA Oncol; 2017 Sep; 3(9):1257-1265. PubMed ID: 28056114 [TBL] [Abstract][Full Text] [Related]
13. Waldenström macroglobulinemia: a review of pathogenesis, current treatment, and future prospects. Ghafoor B; Masthan SS; Hameed M; Akhtar HH; Khalid A; Ghafoor S; Allah HM; Arshad MM; Iqbal I; Iftikhar A; Husnain M; Anwer F Ann Hematol; 2024 Jun; 103(6):1859-1876. PubMed ID: 37414960 [TBL] [Abstract][Full Text] [Related]
14. Dual NAMPT and BTK Targeting Leads to Synergistic Killing of Waldenström Macroglobulinemia Cells Regardless of MYD88 and CXCR4 Somatic Mutation Status. Cea M; Cagnetta A; Acharya C; Acharya P; Tai YT; Yang C; Lovera D; Soncini D; Miglino M; Fraternali-Orcioni G; Mastracci L; Nencioni A; Montecucco F; Monacelli F; Ballestrero A; Hideshima T; Chauhan D; Gobbi M; Lemoli RM; Munshi N; Treon SP; Anderson KC Clin Cancer Res; 2016 Dec; 22(24):6099-6109. PubMed ID: 27287071 [TBL] [Abstract][Full Text] [Related]
15. Current approach to Waldenström Macroglobulinemia. Ravi G; Kapoor P Cancer Treat Res Commun; 2022; 31():100527. PubMed ID: 35149375 [TBL] [Abstract][Full Text] [Related]